GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (NAS:GLMD) » Definitions » Debt-to-Asset

Galmed Pharmaceuticals (Galmed Pharmaceuticals) Debt-to-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Galmed Pharmaceuticals Debt-to-Asset?

Galmed Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.04 Mil. Galmed Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Galmed Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $16.63 Mil. Galmed Pharmaceuticals's debt to asset for the quarter that ended in Dec. 2023 was 0.00.


Galmed Pharmaceuticals Debt-to-Asset Historical Data

The historical data trend for Galmed Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galmed Pharmaceuticals Debt-to-Asset Chart

Galmed Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 - 0.01 0.01 -

Galmed Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - - - -

Competitive Comparison of Galmed Pharmaceuticals's Debt-to-Asset

For the Biotechnology subindustry, Galmed Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galmed Pharmaceuticals's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Galmed Pharmaceuticals's Debt-to-Asset falls into.



Galmed Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Galmed Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Galmed Pharmaceuticals's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Galmed Pharmaceuticals  (NAS:GLMD) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Galmed Pharmaceuticals Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Galmed Pharmaceuticals's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Galmed Pharmaceuticals (Galmed Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
16 Tiomkin Street, Tel Aviv, ISR, 6578317
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.